Related Experiment Video

Updated: Jun 10, 2025

Intraperitoneal Glucose Tolerance Test, Measurement of Lung Function, and Fixation of the Lung to Study the Impact of Obesity and Impaired Metabolism on Pulmonary Outcomes
08:30

Intraperitoneal Glucose Tolerance Test, Measurement of Lung Function, and Fixation of the Lung to Study the Impact of Obesity and Impaired Metabolism on Pulmonary Outcomes

Published on: March 15, 2018

14.1K

Evaluation of Oral Glucose Tolerance Test Results in Children with Cystic Fibrosis

Asli Bestas1, Edip Unal1, Amine Aktar Karakaya1

  • 1Department of Pediatric Endocrinology, Dicle University Faculty of Medicine, Diyarbakir, Türkiye.

Sisli Etfal Hastanesi Tip Bulteni
|October 16, 2024
PubMed

Insights

Approximately 1 in 5 cystic fibrosis patients over 10 years old have abnormal glucose tolerance. Oral glucose tolerance tests (OGTT) are recommended over fasting blood glucose for screening CF-related diabetes.

Area of Science:

  • Endocrinology
  • Pulmonology
  • Metabolic Disorders

Background:

  • Current guidelines recommend annual oral glucose tolerance tests (OGTT) for cystic fibrosis (CF) patients over 10.
  • Early detection of glucose metabolism abnormalities is crucial in CF management.

Purpose of the Study:

  • To evaluate OGTT results in CF patients aged 10 and above.
  • To determine the prevalence of abnormal glucose tolerance (AGT) in this population.
  • To compare screening methods for cystic fibrosis-related diabetes.

Main Methods:

  • 46 CF patients aged 10+ underwent OGTT.
  • Data collected included demographics, anthropometrics, lung function (FEV1%), and OGTT results.
  • Patients were categorized into normal glucose tolerance (NGT) and AGT groups for comparison.

Main Results:

  • AGT was detected in 19.5% of patients.
  • Patients with AGT had higher median fasting glucose and mean 120-minute OGTT glucose levels compared to NGT patients (p<0.005).
  • Lower anthropometric and lung function parameters were observed in the AGT group, though not statistically significant.

Conclusions:

  • AGT affects approximately 1 in 5 older CF patients.
  • Nearly half of patients with AGT had normal fasting glucose, highlighting limitations of fasting glucose screening.
  • OGTT is a more effective screening tool for cystic fibrosis-related diabetes than fasting blood glucose in patients aged 10 and above.
Abstract

Keywords:
Cystic fibrosiscystic fibrosis-related diabetesoral glucose tolerance test

More Related Videos

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT08:13

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT

Published on: January 7, 2018

68.0K
Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test06:59

Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test

Published on: November 13, 2016

10.9K

Related Concept Videos

Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.5K
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
164
Overview of Carbohydrate Metabolism01:19

Overview of Carbohydrate Metabolism

Carbohydrate metabolism is a fundamental biochemical process that ensures a constant supply of energy to living cells. The most important carbohydrate is glucose, which can be broken down via glycolysis to enter into the Krebs cycle and eventually lead to the production of ATP through oxidative phosphorylation.
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
764
Diabetes: Symptoms, Diagnosis, and Complications01:15

Diabetes: Symptoms, Diagnosis, and Complications

For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
512
Oral Hypoglycemic Agents: &#945;-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
163
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
142